FDA approves J&J IMAAVY (nipocalimab-aahu) for wAIHA
Johnson & Johnson says the FDA approves IMAAVY (nipocalimab-aahu) as a first-ever treatment for warm autoimmune hemolytic anemia (wAIHA).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.